Watthikorn Pichitporn

Watthikorn Pichitporn

Auto-generated profile, based on publicly available information

Watthikorn Pichitporn

Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KTKanin Thammavaranucupt
Kanin Thammavaranucupt
BPBoonchan Phonyangnok
Boonchan Phonyangnok
WPWatanyu Parapiboon
Watanyu Parapiboon
LWLaddaporn Wongluechai
Laddaporn Wongluechai
WPWatthikorn Pichitporn
Watthikorn Pichitporn
KJKulapong Jayanama
Kulapong Jayanama
Background: Metformin-associated lactic acidosis (MALA) is a rare event but underrecognition may lead to unfavorable outcomes in type 2 diabetes patients. While many risk factors of MALA have been identified, how to reduce mortality from MALA is a matter of debate. This study aimed to explore the factors associated with 30-day mortality amongst MALA patients. Methods: An observational study enrolled patients diagnosed with MALA between January 2014 and December 2017. MALA was defined by a history of metformin administration, metabolic acidosis (arterial blood gas pH <7.35 or HCO3 5 mmol/L). We examined risk factors including age, sex, underlying diseases, current medications, blood tests, disease severity, and dialysis data. Mortality status was identified from medical records or report on telephone. Results: We included 105 MALA patients. Most patients (95.2%) were diagnosed acute kidney injury stage 3 according to KDIGO 2012 definition. The 30-day mortality rate was 36.2% and dialysis rate was 85.7%. The survivors had higher proportions of underlying chronic kidney disease, presence of metabolic acidosis, receiving renal replacement therapy within 6 hours, and haemodialysis, whereas the non-survivors had higher percentage of hypertension and disease severity. Lower APACHE II score (HR = 0.95; 95%CI, 0.91–0.99; p = 0.038), time to dialysis < 6 hours (0.31; 0.14–0.69; 0.004), and haemodialysis (0.20;0.06–0.67; 0.010) were associated with lower 30-day mortality, using multivariate Cox-regression analysis. Conclusions: Mortality rate amongst patients with MALA was high. Early dialysis treatment within 6 hours after admission and haemodialysis were independently associated with lower 30-day mortality. The large scale, well-designed studies need to confirm these encouraging results.

29 May 2024 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
WPWatanyu Parapiboon
Watanyu Parapiboon
STSajja Tatiyanupanwong
Sajja Tatiyanupanwong
KKKamol Khositrangsikun
Kamol Khositrangsikun
TPThanawat Phulkerd
Thanawat Phulkerd
PKPiyanut Kaewdoungtien
Piyanut Kaewdoungtien
NSNattachai Srisawat
Nattachai Srisawat
Key Points: The efficacy of acute peritoneal dialysis is still controversial. There was no significant difference in 28-day mortality between acute peritoneal dialysis and intermittent hemodialysis. Background: Lower delivered dose of acute peritoneal dialysis (PD) in AKI requires less resources but raises concerns regarding adequate solute and water clearance. The relative merits of lower-dose PD versus intermittent hemodialysis remain uncertain. Methods: A multicenter randomized controlled trial compared the outcomes between acute lower-dosage PD (18–24 L per day) and intermittent hemodialysis (three times per week) from May 2018 to January 2021 in patients with AKI. The primary outcome was 28-day mortality rate. Secondary outcomes included 28-day dialysis-free survival and kidney recovery, metabolic profile, and procedure-related complications. Noninferiority of PD to hemodialysis would be demonstrated if the upper bound of the 95% confidence interval ( CI) on risk difference (PD-hemodialysis) in 28-day mortality rates between the two groups was <20%. Results: We included 157 patients (80 allocated to PD and 77 to intermittent hemodialysis). Before KRT initiation, baseline clinical characteristics between groups were comparable. The overall mean age was 57±15 years. The most frequent cause of AKI was sepsis (68%). There was no difference in 28-day mortality between acute PD and intermittent hemodialysis (50% versus 49%, risk difference 0.6 [95% CI, −15.0 to 16.3]), and 28-day dialysis-free survival (42% versus 37%, risk difference 4.6 [95% CI, −11.1 to 20.3]). Mean weekly Kt/V urea was 2.11±1.14 and 2.55±1.11 in the PD and intermittent hemodialysis groups, respectively. The 7-day fluid balance of PD and intermittent hemodialysis patients was not significantly different. There was more frequent intradialytic hypotension in the intermittent hemodialysis group and more frequent hypokalemia in the PD group. Conclusions: In this study of patients with AKI, there was no significant difference in 28-day mortality between acute PD and intermittent hemodialysis.